When the vitreous shrinks, the strong attachment results in a pulling force on the retina, which may lead to visual distortion, decreased visual acuity and central blindness. When the disease progresses the traction may eventually result in the formation of a hole in the macula (called a macular hole).
JETREA ® breaks down the protein fibers which cause the abnormal traction between vitreous and macula. By dissolving these proteins, JETREA ® releases the traction, and helps to complete the detachment of the vitreous from the macula.
Currently the only available treatment is 'observation' or 'watchful waiting' until a patient becomes a surgical candidate, usually at a late stage of the disease. [ 2 ] ,[ 3 ] A patient would then receive a surgical procedure and repair of the retina. However, for many patients this is not a suitable option, as irreversible damage to the retina may have already occurred. [ 4 ] ,[ 5 ]
ThromboGenics continues to work closely with Alcon to support the regulatory activities and help develop the necessary infrastructure so that patients can access this innovative medicine and receive JETREA ® as soon as it becomes available in the respective countries outside US.References [ 1 ] .Alcon internal estimates/data on file [ 2 ] . Idiopathic macular hole. American Academy of Ophthalmology; 2008 [ 3 ] . Stalmans P. Management and intervention strategies for symptomatic vitreomacular adhesions. Retinal Physician 2011 [ 4 ] . Koerner F & Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol 1999;97:449-458 [ 5 ] . Dugel PU, Brown DM, Humayun MS et al. Symptomatic vitreomacular adhesion: diagnosis, pathologic implications, and management. Retina Today 2011; (Suppl):1-14 About JETREA ® (ocriplasmin) JETREA ® (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA ® is indicated for the treatment of symptomatic VMA. In Europe, JETREA ® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA ® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion. JETREA ® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28. JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts